Related Experiment Video
Updated: Jun 22, 2026
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell
Clara Ruz1,2, José Luis Alcantud2, Francisco Vives1,2
1Department of Physiology, Faculty of Medicine, Universidad de Granada, 18016 Granada, Spain.
Abstract:
Mutations in LRRK2 and GBA1 are key contributors to genetic risk of developing Parkinson's disease (PD). To investigate how LRRK2 kinase activity interacts with GBA and contributes to lysosomal dysfunctions associated with the pathology of PD. The activity of the lysosomal enzyme β-Glucocerebrosidase (GCase) was assessed in a human neuroglioma cell model treated with two selective inhibitors of LRKK2 kinase activity (LRRK2-in-1 and MLi-2) and a GCase irreversible inhibitor, condutirol-beta-epoxide (CBE), under 24 and 72 h experimental conditions. We observed levels of GCase activity comparable to controls in response to 24 and 72 h treatments with LRRK2-in-1 and MLi-2. However, GBA protein levels increased upon 72 h treatment with LRRK2-in-1. Moreover, LC3-II protein levels were increased after both 24 and 72 h treatments with LRRK2-in-1, suggesting an activation of the autophagic pathway. These results highlight a possible regulation of lysosomal function through the LRRK2 kinase domain and suggest an interplay between LRRK2 kinase activity and GBA. Although further investigations are needed, the enhancement of GCase activity might restore the defective protein metabolism seen in PD.
Insights
Parkinson's disease (PD) involves LRRK2 and GBA1 mutations. Inhibiting LRRK2 kinase activity increased GBA protein and activated autophagy, suggesting LRRK2 influences lysosomal function and may offer a therapeutic target for PD.
Area of Science:
- Neuroscience
- Genetics
- Cell Biology
Background:
- Mutations in Leucine-rich repeat kinase 2 (LRRK2) and Glucocerebrosidase 1 (GBA1) are significant genetic risk factors for Parkinson's disease (PD).
- Lysosomal dysfunction is a key pathological feature in PD.
- Understanding the interplay between LRRK2 and GBA1 is crucial for developing targeted PD therapies.
Purpose of the Study:
- To investigate the interaction between LRRK2 kinase activity and GBA.
- To explore how this interaction contributes to lysosomal dysfunction in Parkinson's disease pathology.
- To assess the impact of LRRK2 inhibition on GCase activity and related cellular pathways.
Main Methods:
- Utilized a human neuroglioma cell model.
- Administered selective LRRK2 kinase inhibitors (LRRK2-in-1, MLi-2) and a GCase inhibitor (CBE).
- Assessed GCase activity, GBA protein levels, and LC3-II protein levels at 24 and 72 hours.
Main Results:
- LRRK2 inhibition did not alter GCase activity but increased GBA protein levels after 72 hours.
- LC3-II levels increased following both 24 and 72 hours of LRRK2 inhibition, indicating autophagy activation.
- These findings suggest LRRK2 kinase activity may regulate lysosomal function and GBA.
Conclusions:
- LRRK2 kinase activity appears to influence lysosomal function, potentially through an interplay with GBA.
- Activation of the autophagic pathway was observed upon LRRK2 inhibition.
- Enhancing GCase activity via LRRK2 modulation could potentially restore defective protein metabolism in Parkinson's disease.
